Abiraterone Acetate + Bicalutamide + Leuprolide + Prednisone + Relugolix
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Prostate Carcinoma
Conditions
Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Trial Timeline
Jan 31, 2025 → Jul 1, 2029
NCT ID
NCT06650579About Abiraterone Acetate + Bicalutamide + Leuprolide + Prednisone + Relugolix
Abiraterone Acetate + Bicalutamide + Leuprolide + Prednisone + Relugolix is a phase 3 stage product being developed by Sumitomo Pharma for Recurrent Prostate Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06650579. Target conditions include Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent Prostate Carcinoma were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06650579 | Phase 3 | Recruiting |
Competing Products
20 competing products in Recurrent Prostate Carcinoma